MedTrace Logo

Evaluation of Thiosulfate in End Stage Renal Disease and Kidney Transplantation

NCT04292184 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-12-12

No results posted yet for this study

Summary

Kidneys retrieved from deceased donors will be randomized for conventional perfusion (University of Wisconsin: UW) with or without supplementation of thiosulfate, a major H2S metabolite, and transpl anted thereafter. Recipient's renal function will be assessed prospectively to determine if thiosulfate improves allograft function.

Conditions

  • End Stage Renal Disease (ESRD)

Interventions

DRUG

Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%

The kidney will have 100 mL of 500µM STS added directly to the existing pulsatile perfusion solution at 4°C.

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Alp Sener, Dr. · LHSC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-21
Primary Completion
2022-11-01
Completion
2022-11-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04292184 on ClinicalTrials.gov